Special Emphasis Panel for Cancer Immunotherapeutics – CII (80)
The special emphasis panel for cancer immunotherapeutics reviews applications addressing immunologic therapies of cancer and modulation of the innate and adaptive immune responses to cancer cells. This includes in vitro studies, the evaluation of immunotherapeutic strategies in preclinical models, and translational studies leading to pilot and/or phase-I clinical trials.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Early development of antibody drug conjugates to target tumor cells in vivo or to modulate immune response to cancer cells
- Gene therapy to modulate tumor immune responses
- Drug-induced modulation of immune responses in cancer patients
- Immune modulation with growth factors and growth factor antagonists in model systems of tumors or in patients with cancer
- Use of signal agonists and antagonists that affect immune responses to tumors (e.g., anti-CTLA-4, anti-PD-1 therapy)
- Use of protein, DNA, and RNA as biological response modifiers, such as ribozymes and anti-sense oligonucleotides
- Alteration of susceptibility of tumors to innate and adaptive immunologic responses
